The United States platelet rich plasma market size reached USD 271.7 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 581.2 Million by 2033, exhibiting a growth rate (CAGR) of 8.38% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 271.7 Million |
Market Forecast in 2033
|
USD 581.2 Million |
Market Growth Rate (2025-2033) | 8.38% |
Platelet-rich plasma (PRP) refers to a concentrated plasma protein that contains minor quantities of red blood cells. The platelets are suspended in a small amount of plasma after centrifugation and stimulate healing when injected into the body. PRP is widely administered by non-invasive therapies for long-lasting rejuvenation of ligaments and muscle fibers. Some of the common variants of PRP include pure platelet-rich plasma (P-PRP), leukocyte- and platelet-rich plasma (LPRP), leukocyte- and platelet-rich Fibrin (L-PRF), and pure platelet-rich fibrin (P-PRF).
The rising prevalence of chronic tendon injuries in vital organs is currently bolstering the demand for PRP-based therapies in the US. Furthermore, increasing adoption of effective therapies for treating muscle and acute ligament tearing, arthritis, fractures, orthopedic impairments, etc., is also propelling the market growth. In line with this, the growing awareness towards numerous benefits of PRP treatment in preventing inflammation, encouraging new cartilage formulation, and inducing natural lubrication fluid production, is further augmenting the product demand in the country. Moreover, the rising deployment of advanced healthcare facilities for sports clubs and teams is also catalyzing the adoption of PRP-based therapies for treating common injuries in athletes, such as lumbar spine disc pain, rotator cuff injuries, shoulder pain and instability, tennis/golfer’s elbow, etc. Apart from this, the expanding cosmetic surgery sector in the United States is further driving the utilization of PRP-based procedures for improving facial shape and volume. In the coming years, the increasing healthcare expenditures along with the rising demand for non-invasive medical procedures will continue to spur the demand for PRP-based therapies in the United States.
IMARC Group provides an analysis of the key trends in each sub-segment of the United States platelet rich plasma market report, along with forecasts at the country level from 2025-2033. Our report has categorized the market based on product type, origin, application, and end user.
Breakup by Product Type:
Breakup by Origin:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Arteriocyte Medical Systems Inc. (Isto Technologies II LLC), Arthrex Inc., Depuy Synthes, Inc. (Johnson & Johnson), Dr Prp USA LLC, EmCyte Corporation, Exactech Inc., Glofinn America LLC (Glofinn Co. Ltd.), Regen Lab USA LLC, Stryker Corporation, Terumo BCT Inc. (Terumo Corporation), ThermoGenesis Holdings Inc. and Zimmer Biomet Holdings Inc.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Product Type, Origin, Application, End User, Region |
Region Covered | Northeast, Midwest, South, West |
Companies Covered | Arteriocyte Medical Systems Inc. (Isto Technologies II LLC), Arthrex Inc., Depuy Synthes, Inc. (Johnson & Johnson), Dr Prp USA LLC, EmCyte Corporation, Exactech Inc., Glofinn America LLC (Glofinn Co. Ltd.), Regen Lab USA LLC, Stryker Corporation, Terumo BCT Inc. (Terumo Corporation), ThermoGenesis Holdings Inc. and Zimmer Biomet Holdings Inc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The United States platelet rich plasma market was valued at USD 271.7 Million in 2024.
We expect the United States platelet rich plasma market to exhibit a CAGR of 8.38% during 2025-2033.
The rising consumer awareness towards numerous benefits associated with platelet rich plasma treatment, such as preventing inflammation, encouraging new cartilage formulation, inducing natural lubrication fluid production, etc., is primarily driving the United States platelet rich plasma market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective cosmetic, orthopedics, and neuro surgical procedures to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the United States market for platelet rich plasma.
Based on the product type, the United States platelet rich plasma market has been divided into pure platelet-rich plasma (P-PRP), leukocyte- and platelet-rich plasma (LPRP), leukocyte- and platelet-rich fibrin (L-PRF), and pure platelet-rich fibrin (P-PRF). Among these, pure platelet-rich plasma (P-PRP) currently exhibits a clear dominance in the market.
Based on the origin, the United States platelet rich plasma market can be categorized into autologous PRP, homologous PRP, and allogeneic PRP. Currently, autologous PRP accounts for the majority of the total market share.
Based on the application, the United States platelet rich plasma market has been segregated into orthopedics, cosmetic surgery and dermatology, neurosurgery, general surgery, cardiothoracic surgery, urology, ophthalmology, and others. Among these, orthopedics currently exhibit a clear dominance in the market.
Based on the end user, the United States platelet rich plasma market can be bifurcated into hospitals and clinics, research institutes, and others. Currently, hospitals and clinics hold the largest market share.
On a regional level, the market has been classified into Northeast, Midwest, South, and West, where West currently dominates the United States platelet rich plasma market.
Some of the major players in the United States platelet rich plasma market include Arteriocyte Medical Systems Inc. (Isto Technologies II LLC), Arthrex Inc., Depuy Synthes, Inc. (Johnson & Johnson), Dr Prp USA LLC, EmCyte Corporation, Exactech Inc., Glofinn America LLC (Glofinn Co. Ltd.), Regen Lab USA LLC, Stryker Corporation, Terumo BCT Inc. (Terumo Corporation), ThermoGenesis Holdings Inc., and Zimmer Biomet Holdings Inc.